Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ELIXINOL WELLNESS LIMITED Call Transcript 2018

Aug 23, 2018

64891_rns_2018-08-23_0f0efe49-1ef3-4e42-8217-65c0452deb0d.pdf

Call Transcript

Open in viewer

Opens in your device viewer

==> picture [131 x 91] intentionally omitted <==

ASX Announcement

24 August 2018

Elixinol Global 1H FY2018 results conference call

Elixinol Global Limited (ASX: EXL), a global company operating in the industrial hemp, dietary supplements and emerging medicinal cannabis sectors, is pleased to invite investors to participate in the 1H FY2018 results presentation by Chief Executive Officer, Paul Benhaim on Wednesday 29 August at 11:00 am (AEST / Sydney time).

During the call, Paul Benhaim will present the Company’s half yearly results, followed by a Q&A session.

Date and time

Wednesday 29 August at 11:00 am (AEST / Sydney time)

Dail-in details Australia 1800 123 296 United Kingdom 0808 234 0757 United States 1855 293 1544 Hong Kong 800 908 865 Singapore 800 616 2288 Conference ID 3487404

The event will be recorded and a replay will be made available following the session.

About Elixinol Global

Elixinol Global Limited (ASX: EXL) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, food and wellness products, as well as the cultivation and manufacture of medicinal cannabis products. Elixinol Global’s businesses include:

  • Elixinol USA, which was founded in 2014, is a manufacturer and global distributor of industrial hemp based dietary supplement and skincare products, with operations based out of Colorado, USA;

  • Hemp Foods Australia, which was founded in 1999, is the premier hemp food wholesaler, retailer, manufacturer and exporter in the southern hemisphere of bulk and branded raw materials, and finished products;

  • Elixinol Australia, which was founded in 2014 to participate in the emerging Australian medicinal cannabis market and has submitted licence applications for cultivation and manufacture to the Office of Drug Control (ODC) in early CY 2018. These applications are currently pending approval.

See more at www.elixinolglobal.com

ELIXINOL GLOBAL LIMITED ACN 621 479 794 | PO BOX 20547, WORLD SQUARE NSW 2002 AUSTRALIA [email protected] | WWW.ELIXINOLGLOBAL.COM | +61 2 4044 4585